Publications

* denotes equal contribution

Preprints

    Publications

    1. De Vincentis, A., Tavaglione, F., Namba, S., Kanai, M., Okada, Y., Kamatani, Y. et al. Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population. Alimentary Pharmacology & Therapeutics (2024). 　　

    2. Lo Faro, V., Bhattacharya, A., Zhou, W., Zhou, D., Wang, Y., ..., Namba, S. et al. Novel ancestry-specific primary open-angle glaucoma loci and shared biology with vascular mechanisms and cell proliferation. Cell Reports Medicine 5, 101430 (2024). 　　

    3. Suzuki, K., Hatzikotoulas, K., Southam, L., Taylor, H. J., Yin, X., ..., Namba, S. et al. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature 627, 347–357 (2024). 　　

    4. Koyanagi, Y. N., Nakatochi, M., Namba, S., Oze, I., Charvat, H., Narita, A. et al. Genetic architecture of alcohol consumption identified by a genotype-stratified GWAS and impact on esophageal cancer risk in Japanese people. Science Advances 10, (2024). 　　

    5. Campos, A. I., Namba, S., Lin, S.-C., Nam, K., Sidorenko, J., Wang, H. et al. Boosting the power of genome-wide association studies within and across ancestries by using polygenic scores. Nature Genetics 55, 1769–1776 (2023). 　　

    6. Sato, G., Shirai, Y., Namba, S., Edahiro, R., Sonehara, K., Hata, T. et al. Pan-cancer and cross-population genome-wide association studies dissect shared genetic backgrounds underlying carcinogenesis. Nature Communications 14, (2023). 　　

    7. Tanaka, H., Okada, Y., Nakayamada, S., Miyazaki, Y., Sonehara, K., Namba, S. et al. Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping. Annals of the Rheumatic Diseases 83, 242–252 (2023). 　　

    8. Sekita, A., Kawasaki, H., Fukushima-Nomura, A., Yashiro, K., Tanese, K., ..., Namba, S. et al. Multifaceted analysis of cross-tissue transcriptomes reveals phenotype–endotype associations in atopic dermatitis. Nature Communications 14, (2023). 　　

    9. Edahiro, R., Shirai, Y., Takeshima, Y., Sakakibara, S., Yamaguchi, Y., ..., Namba, S. et al. Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity. Nature Genetics 55, 753–767 (2023). 　　

    10. Wang, Y., Namba, S., Lopera, E., Kerminen, S., Tsuo, K., Läll, K. et al. Global Biobank analyses provide lessons for developing polygenic risk scores across diverse cohorts. Cell Genomics 3, 100241 (2023). 　　

    11. Tsuo, K., Zhou, W., Wang, Y., Kanai, M., Namba, S., Gupta, R. et al. Multi-ancestry meta-analysis of asthma identifies novel associations and highlights the value of increased power and diversity. Cell Genomics 2, 100212 (2022). 　　

    12. *Namba, S., *Saito, Y., Kogure, Y., Masuda, T., Bondy, M. L., Gharahkhani, P. et al. Common germline risk variants impact somatic alterations and clinical features across cancers. Cancer Research 83, 20–27 (2022). 　　

    13. Zhou, W., Kanai, M., Wu, K.-H. H., Rasheed, H., Tsuo, K., ..., Namba, S. et al. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease. Cell Genomics 2, 100192 (2022). 　　

    14. *Namba, S., *Konuma, T., Wu, K.-H., Zhou, W. & Okada, Y. A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. Cell Genomics 2, 100190 (2022). 　　

    15. *Mishra, A., *Malik, R., *Hachiya, T., *Jürgenson, T., *Namba, S., *Posner, D. C. et al. Stroke genetics informs drug discovery and risk prediction across ancestries. Nature 611, 115–123 (2022). 　　

    16. Yamamoto, K., Sonehara, K., Namba, S., Konuma, T., Masuko, H., Miyawaki, S. et al. Genetic footprints of assortative mating in the Japanese population. Nature human behaviour 7, 65–73 (2022). 　　

    17. Wang, Q. S., Edahiro, R., Namkoong, H., Hasegawa, T., Shirai, Y., ..., Namba, S. et al. The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force. Nature communications 13, 4830 (2022). 　　

    18. Namkoong, H., Edahiro, R., Takano, T., Nishihara, H., Shirai, Y., ..., Namba, S. et al. DOCK2 is involved in the host genetics and biology of severe COVID-19. Nature 609, 754–760 (2022). 　　

    19. Shirai, Y., Nakanishi, Y., Suzuki, A., Konaka, H., Nishikawa, R., ..., Namba, S. et al. Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component. Annals of the rheumatic diseases 81, 1301–1312 (2022). 　　

    20. Ho, W.-K., Tai, M.-C., Dennis, J., Shu, X., Li, J., ..., Namba, S. et al. Polygenic risk scores for prediction of breast cancer risk in Asian populations. Genetics in medicine 24, 586–600 (2022). 　　

    21. Namba, S., Ueno, T., Kojima, S., Kobayashi, K., Kawase, K., Tanaka, Y. et al. Transcript-targeted analysis reveals isoform alterations and double-hop fusions in breast cancer. Communications biology 4, 1320 (2021). 　　

    22. Namba, S., Sato, K., Kojima, S., Ueno, T., Yamamoto, Y., Tanaka, Y. et al. Differential regulation of CpG island methylation within divergent and unidirectional promoters in colorectal cancer. Cancer science 110, 1096–1104 (2019). 　　

    Reviews (Japanese)

    1. Namba, S. & Okada, Y. [CURRENT PIPELINES FOR WHOLE-GENOME SEQUENCING ANALYSES]. Arerugi 72, 1110–1112 (2023). 　　

    2. Namba, S. & Okada, Y. [UTILIZING GENOMIC INFORMATION FOR BIOMARKER IDENTIFICATION AND GENOMIC DRUG DISCOVERY]. Arerugi 69, 952–957 (2020).